Immune Score Predicts Outcomes of Gastric Cancer Patients Treated with Adjuvant Chemoradiotherapy

Table 1

Correlation between IS and clinical parameters.

Variables	Immunoscore			value
	Low	Median	High
	n = 20	n = 57	n = 24
	(19.8%)	(56.4%)	(23.8%)
Sex
Male	15(21.4%)	39(55.7%)	16(22.9%)	0.876
Female	5(16.1%)	18(58.1%)	8(25.8%)
Age				0.311
<65	11(17.7%)	33(53.2%)	18(29.0%)
≥65	9(23.1%)	24(61.5%)	6(15.4%)
ECOG				0.433
0	13(21.0%)	32(51.6%)	17(27.4%)
1	7(17.9%)	25(64.1%)	7(17.9%)
LDH (U/L)				0.999
<250	18(20.2%)	50(56.2%)	21(23.6%)
≥250	2(22.2%)	5(55.6%)	2(22.2%)
Unknown	0(0.0%)	2(66.7%)	1(33.3%)
CEA (ng/ml)				0.492
<5	16(19.3%)	45(54.2%)	22(26.5%)
≥5	1(14.3%)	6(85.7%)	0(0.0%)
Unknown	3(30.0%)	5(50.0%)	2(20.0%)
Tumor location				0.248
Upper 1/3	5(23.8%)	9(42.9%)	7(33.3%)
Middle 1/3	4(26.7%)	10(66.7%)	1(6.7%)
Lower 1/3	9(15.5%)	33(56.9%)	16(27.6%)
Total stomach	2(28.6%)	5(71.4%)	0(0.0%)
Tumor size (cm)				0.029
<5	7(12.3%)	32(56.1%)	18(31.6%)
≥5	13(29.5%)	25(56.8%)	6(13.6%)
Surgery type				0.010
Subtotal gastrectomy	8(12.1%)	38(56.7%)	20(30.3%)
Total gastrectomy	12(34.3%)	19(54.3%)	4(11.4%)
Differentiation grade				0.092
Moderate	3(8.8%)	20(58.8%)	11(32.4%)
Poor	17(25.4%)	37(55.2%)	13(19.4%)
Borrmann classification				0.339
I	0(0%)	2(66.7%)	1(33.3%)
II	3(15.8%)	9(47.4%)	7(36.8%)
III	14(21.2%)	36(54.5%)	16(24.2%)
IV	3(23.1%)	10(76.9%)	0(0%)
pT				0.006
1	0(0.0%)	1(16.7%)	5(83.3%)
2	0(0.0%)	6(66.7%)	3(33.3%)
3	4(11.8%)	23(67.6%)	7(20.6%)
4	16(30.8%)	27(51.9%)	9(17.3%)
pN				0.023
0	0(0.0%)	5(71.4%)	2(28.6%)
1	0(0.0%)	10(90.9%)	1(9.1%)
2	4(15.4%)	11(42.3%)	11(42.3%)
3	16(28.1%)	13(54.4%)	10(17.5%)
pTNM				0.009
Stage II	0(0.0%)	14(63.6%)	8(36.4%)
Stage III	20(25.3%)	43(54.4%)	16(20.3%)
LVI				0.020
Negative	2(5.4%)	24(64.9%)	11(29.8%)
Positive	18(28.1%)	33(51.6%)	13(20.3%)
PNI				0.673
Negative	6(15.4%)	23(59.0%)	10(25.6%)
Positive	14(22.6%)	34(54.8%)	14(22.6%)

Values in bold with  < 0.05. LVI, lymphatic and vascular invasion; PNI, perineural invasion.